Alkermes (NASDAQ:ALKS – Get Free Report) had its price target lifted by equities research analysts at HC Wainwright from $43.00 to $50.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the stock. HC Wainwright‘s target price indicates a potential upside of 9.43% from the stock’s current price.
Several other equities research analysts also recently weighed in on ALKS. TD Cowen reaffirmed a “buy” rating on shares of Alkermes in a research report on Monday, September 21st. Truist Financial initiated coverage on Alkermes in a report on Friday, October 16th. They issued a “buy” rating and a $55.00 price objective for the company. Royal Bank Of Canada restated an “outperform” rating and issued a $56.00 target price on shares of Alkermes in a research note on Tuesday, September 22nd. Piper Sandler restated an “overweight” rating and issued a $65.00 target price (up from $43.00) on shares of Alkermes in a research note on Tuesday, July 28th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Alkermes in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $54.81.
View Our Latest Research Report on ALKS
Alkermes Stock Up 1.8%
NASDAQ:ALKS opened at $45.69 on Wednesday. The firm has a market capitalization of $7.66 billion, a P/E ratio of 104.39 and a beta of 0.32. Alkermes has a 1-year low of $27.00 and a 1-year high of $55.67. The company’s fifty day moving average price is $43.92 and its 200-day moving average price is $40.59. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.30 and a quick ratio of 1.85.
Alkermes (NASDAQ:ALKS – Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.17. The firm had revenue of $480.13 million during the quarter, compared to analysts’ expectations of $463.48 million. Alkermes had a net margin of 3.96% and a return on equity of 4.15%. The firm’s revenue was up 21.8% compared to the same quarter last year. During the same quarter last year, the company posted $0.49 earnings per share. As a group, equities research analysts anticipate that Alkermes will post -0.57 EPS for the current year.
Insider Activity
In related news, SVP Christian Nichols sold 7,576 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $49.23, for a total value of $372,966.48. Following the completion of the transaction, the senior vice president directly owned 102,193 shares in the company, valued at $5,030,961.39. The trade was a 6.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP David Gaffin sold 2,035 shares of the stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $46.17, for a total transaction of $93,955.95. Following the sale, the executive vice president directly owned 219,353 shares in the company, valued at $10,127,528.01. This trade represents a 0.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 22,679 shares of company stock valued at $1,070,940 in the last three months. 4.59% of the stock is currently owned by corporate insiders.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of ALKS. Root Financial Partners LLC purchased a new stake in Alkermes in the 3rd quarter worth $25,000. Ameritas Advisory Services LLC purchased a new position in Alkermes during the second quarter valued at $39,000. Versant Capital Management Inc lifted its holdings in Alkermes by 33.9% during the second quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after purchasing an additional 366 shares in the last quarter. Harbor Investment Advisory LLC purchased a new position in Alkermes during the second quarter valued at $82,000. Finally, C M Bidwell & Associates Ltd. acquired a new stake in shares of Alkermes in the second quarter valued at about $104,000. Institutional investors and hedge funds own 95.21% of the company’s stock.
Key Stories Impacting Alkermes
Here are the key news stories impacting Alkermes this week:
- Positive Sentiment: Third-quarter EPS was $0.09, compared with consensus expectations for a $0.08 loss, and revenue of $480.1 million exceeded the $463.5 million estimate. Revenue rose 21.8% year over year. The earnings and revenue beats may support investor confidence. Alkermes Third Quarter 2026 Financial Results
- Positive Sentiment: Alkermes reiterated its fourth-quarter proprietary net sales outlook of $400 million to $420 million and expects Phase III data for alixorexton in mid-2027. The guidance and upcoming clinical milestone give investors benchmarks and a potential catalyst. Alkermes Outlook and Alixorexton Update
- Neutral Sentiment: EVP David Gaffin sold 2,035 shares, worth about $94,000, reducing his holdings by 0.92%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, making it less indicative of a change in his outlook. SEC Form 4
- Negative Sentiment: Despite the quarterly beat, EPS was down from $0.49 in the year-ago quarter, highlighting weaker per-share earnings compared with last year. Alkermes Q3 Earnings Metrics
About Alkermes
Alkermes plc (NASDAQ:ALKS) is a biopharmaceutical company focused on developing and commercializing medicines for central nervous system diseases. Its research and development activities address conditions including schizophrenia, bipolar disorder, addiction, depression and other neuropsychiatric disorders.
The company’s marketed products include Vivitrol, an extended-release injectable form of naltrexone used to treat alcohol dependence and prevent relapse to opioid dependence; Aristada and Aristada Initio, long-acting injectable formulations of aripiprazole lauroxil for the treatment of schizophrenia; and Lybalvi, a combination of olanzapine and samidorphan approved for schizophrenia and bipolar I disorder in adults.
Founded in 1987, Alkermes is incorporated in Ireland and maintains its corporate headquarters in Waltham, Massachusetts.
Featured Articles
- Five stocks we like better than Alkermes
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
